Degree in Applied Biology (2006) and a PhD in Health Sciences (2011) from the University of Minho, Portugal. In 2012 was Associated Professor of Molecular&Cell Biology and Genetics at the Faculty of Health Sciences Dr. Paulo Prata, Barretos in Brazil. Simoultaneously, did a voluntary postdoc at the Molecular Oncology Research Center, Barretos, Brazil where is still a collaborative researcher. Was teacher and supervisor (2013-2016) in the Pos-graduation program in Oncology (Master and PhD) at the “Instituto de Ensino e Pesquisa da Fundação Pio XII”, Hospital de Câncer de Barretos. Backing to Portugal, received 2 postdoctoral fellowship and two auxiliary research contracts in the oncobiology field at Life and Health Sciences Research Institute (ICVS), University of Minho, where is actually Junior researcher. The main research interests are: molecular targeted therapies in oncology; receptor tyrosine kinases (RTKs) and Raf Kinase Inhibitor Protein (RKIP) – biologic functions, signaling, and potential therapeutic targeting in solid tumors. Participated in various competitive national and international projects and actually leads a group of 6 PhD and 1 master student which develop their works in the field of RKIP and Brachyury proteins as prognostic and predictive biomarkers to therapy response in several solid tumors, mainly lung, cervical and prostate cancer.
To date, my work resulted in the publication of 49 papers (15 as 1st author and 5 as corresponding author), with a total IF of 171.6, 1335 citations and H-index=23.
Degree in Applied Biology (2006) and a PhD in Health Sciences (2011) from the University of Minho, Portugal. In 2012 was Associated Professor of Molecular&Cell Biology and Genetics at the Faculty of Health Sciences Dr. Paulo Prata, Barretos in Brazil. Simoultaneously, did a voluntary postdoc at the Molecular Oncology Research Center, Barretos, Brazil where is still a collaborative researcher. Was teacher and supervisor (2013-2016) in the Pos-graduation program in Oncology (Master and PhD) at the “Instituto de Ensino e Pesquisa da Fundação Pio XII”, Hospital de Câncer de Barretos. Backing to Portugal, received 2 postdoctoral fellowship and two auxiliary research contracts in the oncobiology field at Life and Health Sciences Research Institute (ICVS), University of Minho, where is actually Junior researcher. The main research interests are: molecular targeted therapies in oncology; receptor tyrosine kinases (RTKs) and Raf Kinase Inhibitor Protein (RKIP) – biologic functions, signaling, and potential therapeutic targeting in solid tumors. Participated in various competitive national and international projects and actually leads a group of 6 PhD and 1 master student which develop their works in the field of RKIP and Brachyury proteins as prognostic and predictive biomarkers to therapy response in several solid tumors, mainly lung, cervical and prostate cancer.
To date, my work resulted in the publication of 49 papers (15 as 1st author and 5 as corresponding author), with a total IF of 171.6, 1335 citations and H-index=23.
1. Cardoso-Carneiro D, Raquel-Cunha A, Pinheiro J, Gabriela-Freitas M, Fontão P, Reis RM, Martinho O. Implications of RKIP protein in cancer prognosis and therapy response: a literature update. In “Prognostic and Therapeutic Applications of RKIP in Cancer”, Chapter 20, Bonavida B. & Baritaki S., Elsevier. 2020. Pages 389-414
2. Raquel-Cunha A, Cardoso-Carneiro D, Reis RM, Martinho O. Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: behind RTK signaling. Cells 2019, 8(5), 442.
3. Gabriela-Freitas M, Pinheiro J, Raquel-Cunha A, Cardoso-Carneiro D, Martinho O. RKIP as an Inflammatory and Immune System Modulator: Implications in Cancer. Biomolecules 2019 Nov 22;9(12):769.
4. Martinho O*, Silva-Oliveira R, Cury FP, Barbosa AM, Granja S, Evangelista AF, Marques F, Miranda-Gonçalves V, Cardoso-Carneiro D, de Paula FE, Zanon M, Scapulatempo-Neto C, Moreira MA, Baltazar F, Longatto-Filho A, Reis RM. HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors. Theranostics 2017; 7(3):717-732. (*Corresponding author).
5. Miranda-Gonçalves V, Cardoso-Carneiro D, Valbom I, Cury FP, Silva VA, Granja S, Reis RM, Baltazar F, Martinho O. Metabolic reprogramming underlying bevacizumab therapy in glioblastoma cells. Oncotarget. 2017 Oct 10;8(61):103657-103670
6. Moniz S*, Martinho O*, Pinto F, Sousa B, Loureiro C, Oliveira MJ, Moita LF, Honavar M, Pinheiro C, Pires M, Lopes JM, Jones C, Costello JF, Paredes J, Reis RM, Jordan P. Loss of WNK2 expression by promoter gene methylation occurs in adult gliomas and triggers Rac1-mediated tumour cell invasiveness. Hum Mol Genet. 2013 Jan 1;22(1):84-95 (* Co-authorship)
7. Martinho O, Pinto F, Granja S, Miranda-Gonçalves V, Moreira MA, Ribeiro LF, di Loreto C, Rosner MR, Longatto-Filho A, Reis RM. RKIP inhibition in cervical cancer is associated with higher tumor aggressive behavior and resistance to cisplatin therapy. PLoS One. 2013;8(3):e59104.
– Active Member of the international Consortium: “Raf Kinase Inhibitory Protein Consortium” (https://www.rkip.info/members-1 )
– The ISOBM (The International Society of Oncology and Biomarkers) Merit Award, with the work “Effectiveness of Receptor Tyrosine Kinases (RTKs) Targeted Therapies in Glioblastoma” at the ISOBM 2011 Annual Meeting, held on October 15–19, 2011 in Firenze.
– International Invited Lecture: “RKIP as a modulator of oncogene targeted therapy response in solid tumors.” 2nd International Symposium on Prognostic and Therapeutic Implications of RKIP in Cancer. 9–10th May 2019, Heraklion, Crete, Greece.
Prostate cancer (PCa) is the second leading cause of cancer-related deaths in men and therapy resistance is a major problem for PCa patients. Recently, we identified…
Raf kinase inhibitor protein (RKIP), was first described as an inhibitor of MAPK pathway, which accounts for its current name. However, subsequent studies have shown that…
Remote patient monitoring (RPM) of cancer diseases can be potentially used to increase current predictive rates, while contributing for a more cost-effective and accessible diagnosis and treatment…
Phone: +351 253 604 967
Fax: +351 253 604 809
Email: icvs.sec@med.uminho.pt
Life and Health Sciences
Research Institute (ICVS)
School of Medicine,
University of Minho,
Campus de Gualtar
4710-057 Braga
Portugal
Copyright ©2022 ICVS. All Rights Reserved
Copyright ©2022 ICVS. All Rights Reserved
Life and Health Sciences
Research Institute (ICVS)
School of Medicine,
University of Minho,
Campus de Gualtar
4710-057 Braga
Portugal
Copyright ©2022 ICVS. All Rights Reserved
Life and Health Sciences
Research Institute (ICVS)
School of Medicine,
University of Minho,
Campus de Gualtar
4710-057 Braga
Portugal
